Company intelligence / Profile preview

Varian Biopharmaceuticals, Inc.

Ownership: Private
Development stage: Preclinical

Overview

Varian Biopharmaceuticals develops novel small molecule inhibitors targeting atypical protein kinase C iota for oncology. Its lead programs are in preclinical development for basal cell carcinoma and solid tumors. The company’s approach aims to deliver best-in-class potency and selectivity against a validated oncogenic target implicated in multiple cancers. No clinical results have been reported yet.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

VAR-101

Pre-clinical

Indications: Basal cell carcinoma

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Varian Biopharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Varian Biopharmaceuticals, Inc..